Progyny (NASDAQ:PGNY) Releases FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.980-2.09 for the period, compared to the consensus estimate of 1.740. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Progyny Stock Up 2.5%

NASDAQ:PGNY traded up $0.46 during trading hours on Thursday, reaching $19.16. 1,791,103 shares of the stock were exchanged, compared to its average volume of 1,489,923. The business has a 50-day moving average of $17.91 and a two-hundred day moving average of $21.69. Progyny has a twelve month low of $16.10 and a twelve month high of $28.75. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 29.48, a PEG ratio of 1.09 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.06. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS. On average, research analysts forecast that Progyny will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of recent research reports. KeyCorp cut their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Barclays cut their price objective on Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Finally, Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.91.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 7,455 shares of company stock valued at $129,515 in the last three months. Corporate insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Several large investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after acquiring an additional 44,642 shares in the last quarter. Wellington Management Group LLP boosted its stake in Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares in the last quarter. Geode Capital Management LLC boosted its stake in Progyny by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after acquiring an additional 20,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Progyny by 12.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock valued at $43,966,000 after acquiring an additional 184,679 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.